| 摘要 |
Disclosed is the use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect or an anti-tumour in a human, optionally when the human is additionally being treated with ionising radiation, wherein the ZD6474 and ZD1839 may be administered simultaneously, sequentially or separately and wherein the effect of such a combination treatment is synergistic. Also disclosed is a pharmaceutical composition which comprises ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.
|
